ICYMI: Aducanumab Q & A

ICYMI: Aducanumab Q & A

Experts from the University of Wisconsin School of Medicine and Public Health recently shared insight and answered audience questions about aducanumab (marketed as Aduhelm) via a Facebook Live presentation. Learn how this new treatment for Alzheimer’s disease targets amyloid protein buildup, possible side effects of taking the drug and the issue of equal representation in the studies that contributed to aducanumab’s approval. Watch the recording